Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903062 | 0.87 | UBE2T (0.54) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL1127709 | 0.86 | UBE2T (0.61) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL28984544 | 0.83 | KDM4E (0.56) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL1904314 | 0.83 | UBE2T (0.54) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL30306722 | 0.83 | PTGS1 (0.57) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL30306697 | 0.83 | KDM4E (0.56) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL9306082 | 0.83 | SMN1; SMN2 (0.61) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL28984550 | 0.83 | PTGS1 (0.57) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL9018537 | 0.83 | UBE2T (0.54) | MAPTALDH1A1L3MBTL1KDM4EKMT2A | |
| SCHEMBL4726116 | 0.83 | UBE2T (0.59) | MAPTALDH1A1L3MBTL1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108948081-A | A kind of Ratiometric fluorescent probe measuring alkaline phosphatase and its synthetic method and application | 青岛科技大学 | 2018-12-07 | — | — | CN | claimed |
| CN-108948081-A | A kind of Ratiometric fluorescent probe measuring alkaline phosphatase and its synthetic method and application | 青岛科技大学 | 2018-12-07 | — | — | CN | disclosed |
| CN-101312948-B | Biaryl substituted heterocycle inhibitors of lTA4H for treating inflammation | DECODE GENETICS EHF | 2015-01-14 | — | — | CN | disclosed |
| EP-1926708-B1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2014-06-18 | — | — | EP | disclosed |
| US-8598359-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2013-12-03 | — | — | US | disclosed |
| CN-100591679-C | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV | 2010-02-24 | — | — | CN | disclosed |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF (IS) | 2009-06-25 | — | — | US | disclosed |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF (IS) | 2009-06-25 | — | — | US | disclosed |
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF (IS) | 2009-06-25 | — | — | US | disclosed |
| CN-101312948-A | Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation | DECODE GENETICS EHF (IS) | 2008-11-26 | — | — | CN | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | disclosed |
| CN-1860117-A | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-08 | — | — | CN | disclosed |
| CN-1856490-A | Benzimidazole, benzothiazole and benzoxazole derivatives and their use as LTA4H modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163462-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | MAPT 4737/4885ALDH1A1 441/4885L3MBTL1 1534/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | MAPT 4737/4885ALDH1A1 441/4885L3MBTL1 1534/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | MAPT 3103/4885ALDH1A1 701/4885L3MBTL1 1348/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | MAPT 3825/4885ALDH1A1 1306/4885L3MBTL1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.